Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Plenary Session: Immunotherapy in Combination, 2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

covers in REAL TIME

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

 In Attendance, steaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

https://www.massbio.org/events/2016-massbio-annual-meeting-1120

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA

http://pharmaceuticalintelligence.com/2016/03/02/2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-cambridge-ma/

Plenary Session: Immunotherapy in Combination

• Pamela Esposito – Moderator, Cancer vaccine space

1. synergies multiple agents,
2. tolerability long tem will be an issue

• John Orloff, Executive Vice President, Head of Research & Development and Chief Scientific Officer, Baxalta

1. CAR-T combined with PD1
2. Combination is the future
3. Partnering wiht other companies
4. Will not build a Biomarker group, rely on others
5. seelct tumors based on tumor tissues in Ovarian cancer
6. late stage acquisitions at Phase iii only
7. R&D sparing when acquision id at Phase II  then Development is taken in House
8. On the shelf manufacturing approach
9. Mix later stage and early internal stage
10. Pancreatic Cancer partner when all other focused on immune oncology
11. Precision Medicine partner, willingness to collaborate
12. complementary expertise in hematology with research discovery teanslational expertise
13. to get in the door of immuno oncology partnerships and acquisition
14. new targets  challenge for FDA

• Helen Sabzevari, CSO & Co-Founder, Compass Therapeutics

1. PD and PD1 – not a monotherapy, combination therapy is a must check point inhibitor
2. Pathways
3. Genomics, Proteomics, predictive markers,
4. identify the combination
5. NIH works on Cancer Vaccine
6. Personalized Vaccine will be part of the combination therapy
7. Immune system : Macrophages, T- cells memory,
8. Immune-therspy is done in combination will be the future of Oncology – Biologics
9. Compass Therapeutics – will be have in 2016 the largest Portfolio of Immuno-Onclogy targets
10. Target discovery to the Clinic
11. TRanslational Biomarket – intrenal Group collaborationwith clinical centers
12. gene sequence each patient
13. Immuno oncollogy is revolutionizing the Oncology THE CORNERSTONE – because RESPONSES that no radiation therapy has achieved are achieved by Immuno therapy
14. Lower toxicity, higher cure rates
15. Destroy the field or be successful
16. standard therapy not every chemo can be combined
17. Pressure from Regulatory
18. Pressure on Pricing
19. Toxicity: what is been combining
20. 450 CLinical Trial in PD and combinations
21. PRECISION IMMUNOLOGY
22. targets that must be biospecific
23. tumor microenvironment

• Robert Ang

1. Cancer Vaccines
2. Agonists, Immune system can’t be compromised to response to immouno therapy,
3. Targeted approach with vaccine or bestepitope of C presentation, mutation expressed mount immuno agains it
4. T cell level, checkpoint will be necessary for late satge PD1 – Start with BMS,
5. Combinations of PD-1
6. PSA – is tolerant – no ideal target
7. Biomarkers is critical
8. Tumor heterogeneity synergies with vaccine targeting technologies, adjavent with check point
9. Tumor level was not researched enough T-Cells in peripheral blood
10. funded last year, BMS collaboration DRUG for DATA not selling assets
11. T-Cells in solid Tumors
12. Nordik transaction over 14 months, mutual beneficial trend,
13. BMS – invested in Immune Oncology need to complement and think broadly in vaccine, Phase III will determine
14. Integrity of the portfolio, partnership are needed for scientific vision to realize the power of the portfolio
15. deal with Pfizer, clinical effort $850Million and $2Billion to come – molecule is the differentiator
16. data depend on strategy each specific deal
17. Immuno combinations to bring cure, the future of that is still fare
18. Immuno-Oncology is the revolution
19. Progression in tumor, monitoring
20. adverse event and quality of life must be integrated beyonf longer life wiht 12 month

Questions from the Floor

1. populations comorbidity
2. BIOSPECIFIC, TRIAL SPECIFIC
3. HUMANIZATION
4. Tolerability – side effects